Introduction
As analytical devices used for detections of various biological analyte, 1 biosensors have been extensively investigated and applied in various fields such as environmental protection,
2, 3
food safety, 4, 5 and healthcare. 6-8 Due to the great achievements in this field, the world market for commercial biosensors reached 12 billion US dollars in 2011 and is expected to exceed 16 billion US dollars in 2018. 1 Among all sensing approaches reported, assays based on electronic platforms have attracted increasing attention. The number of articles referencing 'electronic biosensor' published in a year has been increasing steadily over the past decade (Fig. 1a) . Particularly, assays using field-effect transistor (FET) sensing platforms have been intensively studied and widely applied in virtue of their superior sensitivity, 9, 10 good compatibility with microfabrication processes,
11
and potential for miniaturization. 12 Indeed, over 40% of all articles related to electronic biosensors involved FET-based platforms and publications referencing 'FET biosensor' exceeded 3500 in 2014. The general configuration of a FET device (Fig. 1b) includes a source electrode, a drain electrode and a gate electrode. The current from source to drain (I d ) is modulated by the voltage on gate (V g ). In FET sensing processes, molecular binding events in the gate region leads to a change in the conductance of the transducing layer, which could be correlated to the concentration of analytes. 13 Conventionally, most sensing approaches are based on natural biomolecular pairs such as antibody/antigen due to their superior binding affinity and selectivity. 14, 15 Biosensors based on these approaches have been intensively studied and widely applied in diagnostics and healthcare. Nevertheless, several limitations have also been observed for the sensing approaches based on natural biomolecular pairs. Firstly, the functional structures of natural biomolecules such as antibodies are typically complicated and fragile. Hence, denaturation/deactivation of these molecules can be readily triggered by exposure to typical working environments of biosensors. 16 Meanwhile, these natural biomolecules usually exhibit large molecular sizes, which may significantly contribute to steric hindrance of target molecules in the sensing process. 17, 18 Large molecular size further limits the quantity of receptors immobilized per unit area. 19 Additionally, preparations of natural biomolecules are typically resourceintensive and time-consuming, resulting in high cost of biosensors based on these approaches. 20 Therefore, practical applications of biosensors based on natural biomolecular pairs have been limited by issues such as short shelf-life, insufficient stability and poor reproducibility. Over the past few decades, efforts have been devoted to exploration of sensing approaches that are not based on conventional natural biomolecular pairs.
To date, a variety of synthetic molecules have been proposed as alternative recognition elements to the natural biomolecules in conventional bio-sensing assays. Among these options, liposomes, 21 aptamers 22 and peptides 23 have been intensively explored and widely applied. In response to increasing attentions to alternative recognition elements, several reviews summarizing biosensors based on synthetic recognition elements have been published. 16, [23] [24] [25] These articles summarized advances in the study of detection mechanism, described recent cases and typically included comparisons of detection methodologies such as electronic methods, optical methods, quartz crystal microbalance-based methods, utilizing one particular class of synthetic recognition element. However, a comprehensive summary of assay performances of different synthetic recognition elements would be necessary for the evaluation of their applicability for biosensing. This article therefore offers an overview of the development of electronic biosensors based on non-antibody recognition elements. More specifically, the most recent advances on different categories of non-antibody recognition elements (including liposomes, aptamers and peptides) were highlighted, followed by individual discussions on the development of electronic biosensors based on each category of non-antibody recognition elements. Meanwhile, biosensors based on different categories of non-antibody recognition elements were compared with each other to facilitate understanding of their respective pros and cons. Table 1 summarizes recent advances in sensing assays based on recognition elements mentioned above. The target analyte, limit of detection achieved, methodology used and characteristics of these assays are presented. Table 1 illustrates that, irrespective of the methodology adopted, assays based on synthetic recognition elements have exhibited the capability to detect various analytes (including enzyme, virus, DNA and bacteria) at clinically relevant concentrations. Fig. 1 (a) A search of publications referencing 'electronic biosensor' and 'field-effect transistor biosensor' over the past decade, using Google Scholar. Steady increases have been observed for both topics. The publications related to electronic biosensors exceeded 8000 in 2014 and around 40% of these studies involved FET-based sensing platforms. (b) General configuration of an FET-based sensing platform. Capture of analyte by the recognition element can generate a change in the source-drain current or potential, which can be detected as a signal.
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Liposome-based sensing approaches
Liposomes are self-assembled microscopic vesicles prepared by the hydration of lipid thin film. [45] [46] [47] As shown in Fig. 2 51, 52 food science, 53 and bio-sensing (as recognition elements). 33 Particularly, the application of liposomes in bio-sensing has attracted increasing attention. Previously, liposomes were used as carriers of optical indicators in assays based on fluorescence, 54 surface plasmon resonance (SPR), 55 and colorimetric changes. 56 These optical approaches were facile, rapid yet effective. [57] [58] [59] However, assays based on optical methodologies are inherently limited by insufficient sensitivity, cross-talk issues (especially in fluorescence-based assays) and requirement for sophisticated instrumentation. Therefore, recent efforts have been made to integrate liposomes with other detection methods. Combined with effective transduction methodologies such as electronic transductions, liposomes can be used for molecular detections with ultra-high sensitivity, 33 which can be attributed to the significant signal amplification realized by appropriate reporters. Liposome-based assays for detections of various analytes (e.g. enzymes, viruses and nuclei acids) have been reported. For instance, Damhorst et al. introduced an assay using ions as reporters. 26 In this study, ion-encapsulated dipalmitoylphosphatidylcholine (DPPC) liposomes were employed for electronic detection of viruses. In virtue of the portable impedance sensing platform used, this assay exhibited great potential for point-of-care diagnostic applications. Additionally, this assay may be adapted for viral detections using liposomes as recognition elements upon appropriate selection or modification of liposomes. Wongkaew et al. reported an amperometric detection of chemical molecules on a microfluidic channel. 27 Herein, specific nuclei acid sequences were measured quantitatively using ferri/ferro hexacyanideencapsulated liposomes. Fast (within 5 min) and sensitive (LOD = 12.5 μM), this assay is suitable for diagnostics and healthcare applications. Taylor et al. presented an assay for quantitative detection of glucose using a liposomal enzyme electrode. Glucose oxidases were encapsulated in liposomes and the glucose molecules were detected using a cyclic voltammetry related methodology. A linear response to glucose up to 40 mM was achieved using this assay (Fig. 3a) . 28 Similarly, Graça et al. presented an amperometric glucose biosensor based on glucose oxidase (GOx)-encapsulated liposomes. 30 Herein, GOx were encapsulated in liposomes to preserve their native structures (Fig. 3b) . The sensitivity of this assay was 7.5 times higher than that of its peers using non-encapsulated GOx. Additionally, the proposed assay showed a sensitivity that was significantly higher than previous assays. Yan et al. described an assay for detections of organophosphate pesticides residues. 31 In this assay, acetylcholinesterase (AChE) molecules were encapsulated in phosphatidylcholine liposomes and the porin-embedded lipid membrane allows in pesticide only. The current change was generated by the inhibition reaction of organophosphate pesticides by AChE. Nevertheless, liposomes were not functioning as recognition elements in assays mentioned above. Instead, they were either used as carriers (to screen out other molecules or preserve the natural structure of encapsulants) or tagged with a reporter probe that hybridizes with the target.
More recently, efforts have been made to explore the capability of liposome as recognition element in electronic detections. Zhang et al. reported an amperometric detection of Escherichia coli (E. coli) using 4-nitrophenyl β-D-glucuronide (PNPG) as the recognition element. 32 β-D-glucuronide released from E. coli catalysed the hydrolysis of PNPG to produce 4-nitrophenyl and the concentration of these electroactive molecules is proportional to that of E. coli. Detection of E. coli ranging from 1.5 × 10 2 to 1.0 × 10 6 cfu/mL was demonstrated and the LOD achieved was 100 cfu/mL. Chen et al. reported a liposome-based enzymatic assay for the detection of phospholipase A 2 (Fig. 3c) . 33 In this assay, 2,4,6-trinitrophenol molecules (TNPs, used as reporter) were encapsulated in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC) liposomes. In the presence of target enzymes, rupture of liposomes was triggered and the reporter molecules were released. Once diffused to the surface of reduced graphene oxide (rGO), TNPs adsorb on rGO via π-π interactions and modulate the conductance of the transducing layer due to the presence of electron withdrawing NO 2 groups. 62 Besides the sensitive nature of electronic biosensors, signal enhancement by the excess concentration of reporter molecules encapsulated also made a great contribution to the superior sensitivity of this assay. Additionally, this approach could be extended for detections of other lipid-degrading enzymes or membrane toxins.
Nevertheless, it is notable that liposomes suffer from tedious selection and modification process. 45 and many liposome-Please do not adjust margins
Please do not adjust margins based assays have an issue of low on/off ratio, which could be attributed to encapsulant leakage. 
Aptamer-based sensing approaches
In bio-sensing applications, aptamers are defined as selected single-stranded nucleic acid ligands (DNA or RNA) with high binding affinity and specificity to the target analyte (e.g. protein and inorganic molecules). 63, 64 Attributed to the folding capability upon binding, 65 the binding affinity and specificity of aptamer/target interactions are comparable to that of antibody/antigen interactions. Hence, nucleic acid aptamers are termed as "chemical antibodies" in various cases. 66, 67 In virtue of unprecedented advantages over natural receptors, aptamers have attracted increasing attention in diagnostics and healthcare. [68] [69] [70] [71] For instance, most aptamer-based biosensors exhibit good reproducibility thanks to the wellestablished chemical synthesis routes. 24 Currently, most aptamers are obtained by the systematic evolution of ligands by exponential enrichment (SELEX) process (Fig. 4) . 72, 73 Firstly, a huge nuclei acid library is created and incubated with the target molecule/ligand. The unbound sequences and molecules are removed, while the bound nuclei acids are eluted and amplified by polymerase chain reaction (PCR). As a result, an enriched library is obtained and this new library is used as the starting library in the next cycle. After 6-12 consecutive cycles, the final library is cloned and sequenced. 24, 74 The in vitro selection of aptamers eliminates the need for in vivo immunization of animals, as in the case of antibody production. Additionally, aptamers can be chemically synthesized in an easy and reproducible manner once the sequence is obtained using SELEX. Unlike natural biomolecules, aptamers exhibit excellent stability in harsh environments and are not subject to denaturization, thus suitable for clinical applications. 75 More importantly, significant conformational changes can be observed for aptamers upon target binding, demonstrating great potential for ultra-sensitive assays. 24, 76 Interactions between aptamers and target molecules could be reversed by reversible intermolecular hybridizations, 77 indicating a great potential for development of non-disposable biosensors. Additionally, non-specific adsorptions on nucleic acid interfaces are usually reduced compared with protein interfaces.
Nevertheless, it should be noted that aptamers, especially RNA ones, are readily digested by nucleases. 78 Therefore, it is necessary to reduce concentrations of nucleases to negligible levels for proper functioning of aptamer-based assays. Fig. 4 Schematic of systematic evolution of ligands by exponential enrichment (SELEX) process. A huge nuclei acid library is created and incubated with the target molecule/ligand. Unbound sequences and molecules are removed, while bound ones are eluted and amplified by polymerase chain reaction (PCR) to form an enriched library, which is used as the starting library in the next cycle. Generally, 6-12 consecutive cycles are performed for each target and the final library is cloned and sequenced. 24, 74 To date, aptamers-based assays have been intensively explored and widely applied. Fritz et al. described an ultraselective and label-free assay for DNA detection. 34 Herein, complementary DNA sequences adsorbed on micro-fabricated FET were used as the recognition element. The LOD achieved by this assay was 2-5 nM. Additionally, this assay achieved the detection of a single base mismatch within 12-mer oligonucleotides, demonstrating excellent specificity. Zayats et al. monitored the binding of adenosine (molecule with a relatively low molecular weight) to its corresponding aptamer. 35 An amino-functionalized nucleic acid (named nucleic acid 5 in the study) was used as the aptamer and another nucleic acid (named nucleic acid 6 in the study) was hybridized with the aptamer. The introduction of adenosine triggered the displacement of nucleic acid 6, resulting in changes of the local charge associated with the gate potential (Fig. 5a ). This assay exhibited high specificity (negligible responses to other nucleotides such as cytidine), while the sensitivity was relatively poor (detection limit = 50 µM). Maehashi et al. reported an aptamer-modified carbon nanotube field-effect transistor (CNT-FET) for the detection of immunoglobulin E (IgE). 36 The introduction of IgE caused a significant I d decrease, whose magnitude was proportional to the concentration of IgE. The LOD achieved by this assay was 250 pM. Additionally, this study demonstrated the improved sensing performance of aptamer-modified devices compared with antibody-modified devices under similar experimental conditions. The higher sensitivity of aptamer-modified devices can be attributed to the small size of aptamers, which enables a larger effect of bound IgE molecules on the equilibrium distribution of mobile carriers in the carbon nanotubes by reducing the distances between IgE molecules and the nanotubes to a level below the Debye length (Fig. 5b) . 79, 80 However, none of these studies involved clinical sample detection, which is essential for diagnostic applications. Ruslinda et al. demonstrated the detection of human immunodeficiency virus type 1 Trans-activator transcription (HIV-1 Tat protein) in clinical samples using an FET-based sensor with RNA aptamers as the recognition element (Fig.  5c ). 37 Incubations with HIV-1 Tat protein at concentrations of 100 nM, 10 nM and 1 nM resulted in 91 mV, 49 mV and 20 mV of gate potential shifts in the negative direction, indicating that quantitative measurements were feasible and LOD of this assay was beyond 1 nM. Additionally, the RNA aptamer was demonstrated to be highly specific to the target and cyclic detections were achieved, demonstrating the reusability of the proposed sensor.
More recently, Goda et al. conducted a series of studies in the field of FET-based biosensors using aptamers as the Please do not adjust margins
Please do not adjust margins recognition element. In 2012, an assay using aptamerfunctionalized FET sensor with a gold electrode as extended gate was reported. 38 As a proof-of-concept, detections of adenosine triphosphate (ATP) and adenosine using hairpinstructured DNA aptamers were demonstrated. Capture of the target molecules led to a structural switching of the aptamer from closed loop to open-loop conformations and the release of the preloaded DNA binder (DAPI, positively charged) into the solution (Fig. 6a) . The sensitivities achieved for ATP (below 10 nM) and adenosine (1-10 nM) were significantly improved compared with previous assays. The detection of protein molecules using a similar platform was also demonstrated. 39 Herein, binding of intrinsically charged target protein led to an alteration in the density of charges at the gate/solution interface (Fig. 6b) . Label-free detections of lysozyme and thrombin in the dynamic ranges of 15.2 -1040 nM and 13.4 -1300 nM were demonstrated. The LOD achieved for lysozyme and thrombin were 12.0 nM and 6.7 nM, respectively. More recently, studies revealed that multiple-contact configurations could improve the binding affinity between protein and aptamers. 81 Therefore, Goda et al. developed a novel aptamerfunctionalized potentiometric biosensor with improved affinity for the target protein (Fig. 6c) . 40 In this assay, two different aptamers that recognize different epitopes in thrombin were immobilized (in parallel or serial manners) on the sensing surface to capture the target via multiple contacts. As a result, the sensitivity of this assay was further enhanced (LOD = 5.5 nM) compared to previous reports. 
Peptide-based sensing approaches
As short chains of amino acid oligomers linked by peptide bonds, peptides have the same building blocks as proteins. Hence, these molecules have been used to substitute for proteins for clinical and diagnostic applications. [82] [83] [84] Indeed, peptide-based biosensors have been proposed for detections of various targets, including cells, 43 proteins, 85 ions 86 and small molecules. 87, 88 Distinctive advantages over natural molecules and other synthetic receptors have been reported for peptides. Primarily, peptides exhibit high affinity to particular analytes, 89 which can be attributed to their protein-like nature as multiple interactions can be observed in most binding sites of peptides. The high affinity allows the development of ultra-sensitive and highly specific peptide-based biosensors. Moreover, the affinity can be further enhanced by easy modifications of the peptides. 90 Meanwhile, peptides have shown excellent intrinsic stability in harsh environments (e.g. in the presence of chemical and thermal denaturants). Indeed, peptides are significantly superior to proteins in terms of chemical and conformational stability due to their short-chain structures. 91 As a result, peptide-based biosensors exhibit significantly increased shelf-life compared with antibody-based ones. Also, peptide-based biosensors exhibit a great potential for multiplexed detection. 43 In virtue of various matured protocols that have been reported, peptides can be chemically synthesized in a facile yet cost-effective way once the sequence information is isolated from the phage display (Fig.  7) . 92, 93 Nevertheless, it should be noted that conjugation of a reporter is typically required as peptides do not directly generate a measurable signal in response to a binding event in most assays reported. 23, 90 In other words, label-free detection would be an inherent challenge for peptide-based sensing assays. Additionally, the selectivity of assays with peptides as recognition elements needs to be optimized due to the semiselective binding nature of peptides. 94, 95 Indeed, many peptides have exhibited significant binding affinity towards several different cells/molecules.
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Please do not adjust margins . 41 Herein, peptides were immobilized on Au electrodes via self-assembly and cleaved in the presence of MMP-7 ( Fig. 8a) , resulting in detectable current changes. This assay was facile yet sensitive (LOD = 3.4 pM), and can be extended to detections of infectious agents. Adjémian et al. proposed a similar assay for rapid enzymatic measurements. 42 Herein, peptides were immobilized on Au electrodes via polyethylene glycol (PEG) linkers (Fig. 8b) and detection of proteases (trypsin and α-thrombin) was achieved on the peptide-functionalized electrodes via cyclic voltammetry. Detection of protease at 1 nM was demonstrated on the substrate proposed and this assay was exceptionally rapid (75% cleavage in 1 min for trypsin), which could be attributed to the flexible structure of PEG linkers that allow easy access to cleavage sites for protease molecules. Nevertheless, peptide labelling (with ferrocene reporters) was required in both assays mentioned above, resulting in additional preparation procedures and increased cost. Hence, these assays were not ideal candidatures for diagnostic and clinical applications. Mannoor et al. presented a label-free electronic biosensor for quantitative detections of pathogenic bacteria via impedance spectroscopy. 43 In this assay, gold microelectrode arrays functionalized with antimicrobial peptides were used to capture pathogenic bacteria such as E. coli and Salmonella and impedance changes were generated by the binding events (Fig.  8c) . Significantly, the LOD achieved by this assay was around 100 cfu/mL (equivalently 1 µL
), which is within the clinically relevant range, and the detection was demonstrated to be highly selective as other bacteria (e.g. Gram-negative bacteria) did not trigger significant signals. 97 Additionally, the miniaturized sensing platform exhibited great potential for portable devices that can be used for in situ detections of infectious agents. Johnson et al. proposed a peptide-based label-free impedimetric biosensor for C-reactive protein (CRP), which is a key biomarker for cardiovascular diseases. 44 In this assay, peptide-functionalized electrodes were used for CRP detection based on surface plasmon resonance (SPR), electrochemical impedance spectroscopy (EIS) and cyclic voltammetry. Additionally, antibody-based assay was also demonstrated and compared with its peptide-based peer. The results revealed that the small size of peptides enabled a larger gate accessible to the probes (Fig. 8d) , resulting in a sharp reduction of the charge transfer resistance. More recently, Chen et al. introduced a peptide-functionalized reduced graphene oxide FET (rGO-FET) for ultra-sensitive detection of MMP-7. In this approach, MMP-7 specifically digests negatively charged polypeptides (JR2EC) immobilized on rGO, 98 resulting in a significant reduction of their net charges (Fig. 8e) . In this way, the proposed assay enabled label-free detection of MMP-7 at clinically relevant concentrations with LOD of 10 ng/mL in buffer and 40 ng/mL in human plasma. Additionally, the proposed assay was demonstrated to be highly selective as matrix metalloproteinase-1 (MMP-1), which is an enzyme in the same family as MMP-7, did not trigger detectable changes in I d .
Particularly, the progresses of FET-based sensing platforms were highlighted. These assays are ideal alternatives to conventional assays based on natural molecular pairs, which suffer from fragile and complicated functional structures, large molecular size and sophisticated preparation approaches. Comparisons between antibody-based assays and synthetic receptor-based ones revealed that the synthetic receptorbased assays exhibited better sensing performance in terms of sensitivity. To date, detections of various analytes (including enzyme, virus, DNA and bacteria) at clinically relevant concentrations have been demonstrated using assays based on non-antibody recognition elements.
Each category of assays shows different strengths and limitations: liposome-based assays are rapid and label-free, but suffer from tedious selection and modification process; aptamer-based assays are highly reproducible and function well in harsh environments, while aptamers' sensitivity to hydrolytic digestion by nucleases has been an intrinsic drawback; peptide-based assays are sensitive and costeffective, but suffer from poor selectivity and additional labelling processes in some cases.
Despite the great progress achieved, several issues remain to be solved before clinical applications of these assays. First, the total number of non-antibody recognition elements developed/discovered is still significantly lower than that of antibodies. This can be attributed to the fact that the discovery of these elements remains a trial-and-error process in most cases. Therefore, systematic and universal methodologies are urgently needed. Second, bio-sensing approaches based on non-antibody recognition elements have been severely limited by non-specific binding of target molecules, resulting in significantly reduced sensitivity for clinical samples. Additionally, molecular recognitions by aptamers and peptides need to be fully understood. Nevertheless, it should be noted that research in biosensors based on non-antibody recognition elements is still in its infancy and it is believed that with increasing efforts, these sensing assays will eventually be used for clinical applications and diagnostics. 
